Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab PK/PD/Safety in Healthy Chinese Adults
NCT02135640Phase 1Completed
- Sponsor
- GSK
- Start
- Jul 2014
- Primary completion
- Feb 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of denosumab in osteoporosis (3 arms), sponsored by GSK. Primary endpoint: Subject incidence of treatment-emergent adverse events up to 26 weeks. Started Jul 2014; status: completed.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT02135640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02135640.